

26.02.2026

To
BSE Limited,
Dept. of Corporate Services,
Floor 25, PJ Towers, Dalal Street,
Mumbai-400001.

Scrip Code: 526445

Dear Sir/Madam,

Sub: Outcome of the Board Meeting held on 26th February, 2026**Ref: Regulation 30 and 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.**

With reference to our intimation letter dated February 23, 2026 under Regulation 29 of SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015, we wish to inform that at the meeting of Board of Directors held today i.e., on Thursday, February 26, 2026, the Directors have inter-alia, recorded the following:

1. The approval of Unaudited Financial Results (Standalone and Consolidated) of the Company, for the quarter ended December 31, 2025, as recommended by the Audit Committee at their Meeting held today, pursuant to Regulation 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The statutory auditors have reviewed the financial results and given unmodified opinion (Annexure - 1).
2. Taken note of the resignation of Mr. Dhinakaran Rajagopal as Chief Financial Officer of the Company (Annexure – 2).
3. The approval of appointment of Mr. Kunisetty Venkateswara Rao as the Chief Financial Officer of the Company (Annexure – 3).
4. The approval for availing credit facilities from Indus Finance Limited to the extent of Rs. 5 Crores.
5. That the Company has received an In-principle approval from BSE Limited on September 19, 2025 for its proposed partly paid-up Rights Issue. The Company has resolved to expedite the process and complete the Rights Issue within the prescribed timelines in compliance with applicable provisions of the Securities and Exchange Board of India (ICDR) Regulations, 2018.

The Board also took note of the observations received from BSE Limited regarding certain delays in compliance with Regulations 29 and 33. While the intimations and the Q2 results were filed beyond the prescribed timelines, the Company has since duly submitted the required filings and ensured full compliance with the applicable regulations. The Board further noted that the fine levied by the Exchange has been duly paid. The matter now stands resolved (Annexure 4).

We have attached herewith the copy of the unaudited financial results (standalone and consolidated) for the quarter ended December 31, 2025 along with the Limited Review Report for the said period.

The Board Meeting commenced at 6:30 P.M. and concluded at 9:10 P.M. The necessary arrangements are in place to publish the unaudited financial results in the newspapers. The said financial results will also be available on company's website <https://indrayani.com/fy2025-26> and also on BSE website <https://www.bseindia.com/stock-share-price/indrayani-biotech-ltd/indranib/526445/>.

Kindly take the same on records.

Thanking You,

Yours Faithfully

For Indrayani Biotech Limited

Swaminathan Govindarajan

Whole-time director

DIN: 02481041



Annexure - 1

VENKATESH & CO
Chartered Accountants

Limited Review Report on Quarterly Financial Results of Indrayani Biotech Limited pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015

To
The Board of Directors,
Indrayani Biotech Limited

We have reviewed the accompanying statement of unaudited standalone financial results of **Indrayani Biotech Limited** ('the Company') for the quarter and period ended December 2025. This statement, is the responsibility of the Company's Management and has been approved by the Board of Directors, has been prepared in accordance with the applicable Indian Accounting Standards (Ind AS) specified under Section 133 of the Companies Act, 2013. Our Responsibility is to issue a report on these financial statements based on our review.

We conducted our review of the statement in accordance with the Standard on Review Engagement (SRE) 2410, 'Review of Interim Financial Information Performed by the Independent Auditor of the Entity', issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial results are free of material misstatements. A review is limited primarily to inquiries of Company personnel and analytical procedures applied to financial data and thus provides less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.

Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement of unaudited financial results prepared in accordance with applicable Indian Accounting Standards ('Ind AS') prescribed under Section 133 of the Companies Act, 2013 read with relevant rules issued thereunder and other recognized accounting practices and policies has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 including the manner in which it is to be disclosed, or that it contains any material misstatement.

for Venkatesh & Co

Chartered Accountants

FRN : 004636S

CA Dasaraty V

Partner

M No : 026336

UDIN: **26026336NDKKIB6434**

Chennai, 26th February 2026



"SRI RANGA", New No.151, Mambalam High Road, T.Nagar, Chennai- 600 017.

Telefax: 2814 4763/64/65/66 Email: audit@venkateshandco.com

M/s Indrayani Biotech Limited
L40100TN1992PLC129301

Module # 32, 33, Block-1, SIDCO Electronics Complex, Thiru Vi Ka Industrial Estate, Guindy, Chennai - 600 032
Statement of unaudited Standalone financial results for the quarter ended 31st December, 2025

Rs. In Lakhs

Particulars	Quarter Ended			9 Months Ended		Year ended
	31-12-2025	30-09-2025	31-12-2024	31-12-2025	31-12-2024	31-03-2025
Income From Operations	Unaudited	Unaudited	Unaudited	Unaudited	Unaudited	Audited
Revenue from Operations	520.10	593.13	818.82	1,781.80	2,848.60	3,776.91
Other Income	67.66	182.37	66.21	339.19	258.19	351.60
Total Income from Operations	587.76	775.50	885.03	2,120.99	3,106.79	4,128.51
Expenses						
Cost of Material consumed	203.77	305.98	334.29	845.03	1,198.77	1,478.43
Employee Benefit Expenses	137.68	155.56	269.37	443.39	993.33	1,323.68
Finance Cost	109.29	99.22	152.49	340.44	492.64	732.10
Depreciation and amortization expenses	14.23	16.51	32.34	45.99	96.08	102.49
Other Expenses	112.07	135.60	82.36	355.76	281.58	427.18
Total Expenses	577.04	712.87	870.85	2,030.61	3,062.40	4,063.88
Profit/Loss before exceptional Items and Tax	10.72	62.63	14.18	90.38	44.39	64.63
Provisions (other than tax) and Contingencies						
Add/Less : Exceptional Items						
Profit (+)/ Loss (-) from Ordinary Activities before tax	10.72	62.63	14.18	90.38	44.39	64.63
Tax Expenses	2.70	15.79	3.57	22.75	11.17	-80.00
Net Profit(+)/ Loss(-) from Ordinary Activities after tax	8.02	46.84	10.61	67.63	33.22	144.63
Other Comprehensive income	-	-	-	-	-	-
A) (i) Items that will not be reclassified to profit or loss	-	-	-	-	-	-
(ii) Income tax relating to items that will not be reclassified into profit or loss	-	-	-	-	-	-
B) (i) Items that will be reclassified to profit or loss	-	-	-	-	-	-
(ii) Income tax relating to items that will be reclassified into profit or loss	-	-	-	-	-	-
Total Comprehensive Income for the period	8.02	46.84	10.61	71.37	33.22	144.63
Paid-up equity share capital (Rs.10 being the Face Value per share)	4553.63	4553.63	4553.63	4553.63	4553.63	4553.63
Earnings Per Share (EPS)						
- Basic	0.01	0.10	0.02	0.14	0.07	0.32
- Diluted	0.01	0.10	0.02	0.14	0.07	0.32

Notes:

- The above standalone financial results were reviewed and recommended by the Audit Committee and approved by the Board of Directors at their meeting held on 26th February, 2026 and have been subjected to review by the Statutory Auditors of the company. The above results have been prepared in accordance with the Indian Accounting Standards-(Ind AS) as prescribed under Section 133 of the Companies Act 2013, read with Rule 3 of the Companies (Indian Accounting Standards) Rules, 2015 and Companies (Indian Accounting Standards) Amendment Rules, 2016.
- The financial results are being forwarded to the Bombay Stock Exchange & also available on the company website www.Indrayani.com
- Previous period figures have been regrouped wherever necessary.
- There is no investor complaint received during the this Quarter.

For Indrayani Biotech Limited

G.Swaminathan
Whole-time Director
02481041



VENKATESH & CO
Chartered Accountants

Limited Review Report on consolidated unaudited quarterly to date financial results of the company Pursuant to the regulation 33 of the SEBI (Listing Obligations and disclosure requirements) regulations, 2015

To
The Board of Directors
Indrayani Biotech Limited

We have reviewed the accompanying Statement of Consolidated Financial Results of Indrayani Biotech Limited ("the Parent") and its subsidiaries (the Parent and its subsidiaries together referred to as "the Group") and its share of the net profit after tax and total comprehensive income / loss of its associates for the quarter ended **31st December, 2025** and for the period from 1st April 2025 to 31st December 2025 ("the Statement"), being submitted by the Parent pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended. Attention is drawn to the fact that the consolidated figures for the corresponding quarter ended 31st December, 2024 and corresponding period from 1st April 2024 to 31st December 2024 as reported in these financial results have been approved by the Parent's Board of Directors, but have not been subjected to audit/review.

This Statement, which is the responsibility of the Parent's Management and approved by the Parent's Board of Directors, has been compiled from the related consolidated financial statements which has been prepared in accordance with the Indian Accounting Standards prescribed under Section 133 of the Companies Act, 2013, read with the Companies (Indian Accounting Standards) Rules, 2015, as amended ("Ind AS"), and other accounting principles generally accepted in India. Our responsibility is to express an opinion on the Statement based on our review of such consolidated financial statements.

We conducted our review of the statement in accordance with the Standard on Review Engagement (SRE) 2410, 'Review of Interim Financial Information Performed by the Independent Auditor of the Entity', issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial results are free of material misstatements. A review is limited primarily to inquiries of Company personnel and analytical procedures applied to financial data and thus provides less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.

We also performed procedures in accordance with the circular issued by the SEBI under Regulation 33 (8) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, to the extent applicable.

The Statement includes the results of the entities mentioned in the Annexure – I, is presented in accordance with the requirements of Regulation 33 of the Listing Regulations, as amended;

Based on our review conducted and procedures performed as stated in paragraph above and based on the consideration of the reports of the management referred to in paragraph below, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in the aforesaid Indian Accounting Standard and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements)



"SRI RANGA", New No.151, Mambalam High Road, T.Nagar, Chennai- 600 017.

Telefax: 2814 4763/64/65/66 Email: audit@venkateshandco.com



VENKATESH & CO
Chartered Accountants

Regulations, 2015, as amended, including the manner in which it is to be disclosed, or that it contains any material misstatement.

We did not review the financial statement / financial information of **7 Subsidiaries and 2 step down subsidiaries** included in the consolidated unaudited financial results, whose interim financial information for the Period ended 31st December, 2025 reflects total revenues of **₹ 8,224.90 Lakhs**, total comprehensive profit / (loss) of **₹ 48.08 Lakhs** for the period ended on that date as considered in the consolidated financial results.

This financial information have been reviewed by the Management and our opinion on the consolidated financial results, in so far as it relates to the amounts and disclosures included in respect of these subsidiaries, associates and joint ventures, is based solely on the reports of the Management and the procedures performed by us as stated in paragraph mentioned above.

for Venkatesh & Co

Chartered Accountants

FRN : 004636S



CA Dasaraty V

Partner

M No : 026336

UDIN: **26026336NQQJNY9632**

Chennai, 26th February 2026

"SRI RANGA", New No.151, Mambalam High Road, T.Nagar, Chennai- 600 017.

Telefax: 2814 4763/64/65/66 Email: audit@venkateshandco.com



Annexure I to the Audit Report

List of subsidiaries, associates and joint ventures included in the consolidated Quarterly Unaudited financial results:

S. No.	Name of the entity	Relationship
1	IBL Health Care Limited	Subsidiary
2	HSL Agri Solutions Limited	Subsidiary
3	HSL Prime Properties Private Limited	Subsidiary
4	Healthway India Private Limited	Step Down Subsidiary
5	Dindigul Farm Product Limited*	Subsidiary
6	Matrix Boilers Private Limited	Subsidiary
7	IBL Investments Limited	Subsidiary
8	IBL Social Foundation	Subsidiary
9	Kniss Laboratories Private Limited	Step Down Subsidiary

***Consolidation Comprises of Financial results of Dindigul Farm Product Limited by the virtue of Control established over Board of Directors and decisions of management.**



M/s Indrayani Biotech Limited
CIN: L40100TN1992PLC129301
BLOCK 1, MODULE NO.32 & 33, 3rd FLOOR, SIDCO ELECTRONIC COMPLEX,
THIRU VI KA INDUSTRIAL ESTATE, GUINDY CHENNAI-600032

Statement of unaudited Consolidated financial results for the quarter ended 31st December, 2025

(Rs. In lakhs except per share data)

Particulars	3 months ended	3 months ended	3 months ended	9 months ended	9 months ended	Year Ended
	31 - Dec - 2025	30 - Sep-2025	31- Dec- 2024	31- Dec- 2025	31- Dec- 2024	31- Mar-2025
	Unaudited	Unaudited	Unaudited	Unaudited	Unaudited	Audited
Income From Operations						
Revenue from Operations	3,501.48	3,594.85	1,731.82	10,006.70	7,965.91	13,022.84
Other Income	83.08	180.13	0.38	368.83	34.94	312.58
Total Income from Operations	3,584.56	3,774.98	1,732.20	10,375.53	8,000.85	13,335.42
Expenses						
Cost of Material consumed	2,610.14	2,193.92	1,013.41	6,879.88	4,258.92	8,277.21
Employee Benefit Expenses	319.61	397.47	341.79	986.31	1,427.68	2,046.78
Finance Cost	246.71	188.77	102.60	652.56	469.06	1,176.27
Depreciation and amortization expenses	100.99	130.03	146.16	316.84	508.36	336.81
Other Expenses	292.85	758.74	84.96	1,398.76	1,079.25	2,072.70
Total Expenses	3,570.31	3,668.93	1,688.92	10,234.36	7,743.27	13,909.77
	-					
Profit/Loss before exceptional Items and Tax	14.25	106.05	43.28	141.17	257.58	-574.35
Add/Less : Exceptional Items	-					
Profit/Loss Before tax	14.25	106.05	43.28	141.17	257.58	-574.35
Tax Expenses	2.70	14.83	8.13	22.76	15.73	36.40
Net Profit/Loss for the period from continuing	11.55	91.22	35.15	118.41	241.85	-610.75
Other Comprehensive Income	-					
A (i) Items that will not be reclassified to profit or loss	-					
(ii) Income tax relating to items that will not be reclassified to profit or loss	-					-2.61
B (i) Items that will be reclassified to profit or loss	-					
(ii) Income tax relating to items that will be reclassified to profit or loss	-					
Total Comprehensive income for the period attributable to	11.55	91.21	35.14	118.41	241.85	-613.36
Comprehensive income for the period attributable to the owners of the Company	6.36	40.13	23.86	65.12	128.97	-158.27
Total Comprehensive income for the period attributable to the non-controlling interest	5.20	51.08	11.29	53.29	112.89	-455.09
Paid-up equity share capital (Rs.10 being the Face Value per share)	4,553.63	4,553.63	4,553.63	4,553.63	4,553.63	4,553.63
Earnings Per Share (EPS)						
- Basic	0.01	0.09	0.05	0.14	0.10	-0.35
- Diluted	0.01	0.09	0.05	0.14	0.10	-0.35

Notes:

- The above consolidated financial results were reviewed and recommended by the Audit Committee and approved by the Board of Directors at their meeting held on 26th February, 2026 and have been subjected to review by the Statutory Auditors of the company. The above results have been prepared in accordance with the Indian Accounting Standards-(Ind AS) as prescribed under Section 133 of the Companies Act 2013, read with Rule 3 of the Companies (Indian Accounting Standards) Rules, 2015 and Companies (Indian Accounting Standards) Amendment Rules, 2016.
- The financial results are being forwarded to the Bombay Stock Exchange & also available on the company website www.Indrayani.com
- Previous period figures have been regrouped wherever necessary.
- There is no investor complaint received during this Quarter.

For Indrayani Biotech Limited

Swaminathan Govindarajan
Whole Time Director
DIN: 02481041

Annexure 2

Disclosures related to resignation of Mr. Dhinakaran Rajagopal as Chief Financial Officer

The Details required under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, read with SEBI circulars HO/49/14/14(7)2025-CFD-POD2/I/3762/2026 dated 30th January, 2026:

SI No.	Particulars	Description
1	Reason For Change Viz. Appointment, Resignation, Removal, Death or Otherwise;	Resignation from the post of Chief Financial Officer of the Company due to personal reasons
2	Date of appointment/cessation applicable) & term of appointment;	26th February, 2026
3	Brief profile (in case of appointment)	Not Applicable
4	Disclosure of relationships between directors (in case of appointment of a director).	Not Applicable

Annexure 3

Disclosures related to appointment of Mr. Kunisetty Venkateswara Rao as Chief Financial Officer

The Details required under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, read with SEBI circulars HO/49/14/14(7)2025-CFD-POD2/I/3762/2026 dated 30th January, 2026:

SI No.	Particulars	Description
1	Reason For Change Viz. Appointment, Resignation, Removal, Death or Otherwise;	Appointment as Chief Financial Officer of the Company
2	Date of appointment /cessation applicable) & term of appointment;	27th February, 2026
3	Brief profile (in case of appointment)	<p>Mr. K Venkateswara Rao is a qualified Chartered Accountant and a Bachelor in Commerce. He is a Fellow Member of the Institute of Chartered Accountant of India (ICAI) with over 30 years of extensive experience in the financial sector. He possesses rich expertise in financial management, corporate finance, strategic planning, taxation, audit, compliance, and regulatory matters.</p> <p>Throughout his distinguished career, he has successfully led finance functions across diverse organizations, ensuring strong financial controls, robust governance frameworks, and sustainable business growth. He has significant experience in budgeting, financial reporting, fund management, banking relationships, risk management, and statutory compliance.</p> <p>Mr. K Venkateswara Rao is known for his strategic financial leadership, integrity, and result-oriented approach, contributing effectively to organizational growth and stakeholder value creation.</p>
4	Disclosure of relationships between directors (in case of appointment of a director).	Not related to any directors of the Company

Fwd: Fw: Consent to work as CFO in Indrayani Biotech Limited

From marysujatha@indrayani.com <marysujatha@indrayani.com>
To <cs@indrayani.com>
Date 26/02/2026 04:15 PM

--

Regards
Mary Sujatha
Head HR
Indrayani Biotech Ltd.
BSE Listed Company
Block No. 1, No. 32, 33, 3rd Floor,
SIDCO Electronic Complex,
Thiru-Va-Ka Industrial Estate, Gunidy, Chennai 32
Mobile: +919176633762
LAND LINE: 04424463751
www.indrayani.com

Sent with [Hostinger Mail](#)

----- Forwarded message -----

From: Venkateswara Rao <raokvenkat@yahoo.com>
Date: Thu, Feb 26, 2026 3:51 PM
Subject: Fw: Consent to work as CFO in Indrayani Biotech Limited
To: marysujatha@indrayani.com <marysujatha@indrayani.com>

[Yahoo Mail: Search, organise, conquer](#)

---- Forwarded message ----

From: "Venkateswara Rao"
To: "marysujatha@indrayann.com", "gsnathan10@gmail.com", "nmr.anganathan@gmail.com"
Cc:
Sent: Thu, 26 Feb 2026 at 3:43 pm
Subject: Consent to work as CFO in Indrayani Biotech Limited

Sir/ Madam,

I K. Venkateswara Rao with reference to the above subject, as discussed, herewith given my consent to work as CFO of Indrayani Biotech Limited.

Tks & Rgds
K. Venkateswara Rao

[Yahoo Mail: Search, organise, conquer](#)

Date: 26-02-2026

To,

The Board of Directors,
Indrayani Biotech Limited,
Module 33, 3rd Floor Block 1 SIDCO Electronic Complex,
Thiru-Vi-Ka Industrial Estate,
Guindy Industrial Estate,
Chennai-600032.

Subject: Resignation from the position of Chief Financial Officer.

Dear Sir's,

I hereby tender my resignation from the position of Chief Financial Officer of Indrayani Biotech Limited with effect from 26.02.2026 due to personal reasons.

Yours faithfully,



Dhinakaran Rajagopal
Chief Financial Officer

2/26/26, 12:04 PM

526445-Fines as per SEBI Master Circular No. SEBI/HO/CFD/PoD2/CIR/P/0155 dated November 11, 2024 (Chapter-VII(A)-Penal Actions for Non-Compliance)

From: bse.soplodr <bse.soplodr@bseindia.com>
 To: info@indrayani.com <info@indrayani.com>, indrayanichennai@gmail.com <indrayanichennai@gmail.com>, info@indrayani.com <info@indrayani.com>, CS@INDRAYANI.COM <CS@INDRAYANI.COM>
 Cc: bse.soplodr <bse.soplodr@bseindia.com>
 Date: 16/12/2025 05:01 PM

Ref.: SOP-Review-dated- 16.12.2025

To

The Company Secretary/Compliance Officer

Company Name: Indrayani Biotech Ltd

Scrip Code: 526445

Dear Sir/Madam,

Sub: Fines as per SEBI Master Circular No. SEBI/HO/CFD/PoD2/CIR/P/0155 dated November 11, 2024 (Chapter-VII(A)-Penal Actions for Non-Compliance).

The company is advised to refer to the SEBI Master Circular No. SEBI/HO/CFD/PoD2/CIR/P/0155 dated November 11, 2024 issued by Securities and Exchange Board of India (SEBI) with respect to penal actions prescribed for non-compliance of certain provisions of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 and the Standard Operating Procedure for suspension and revocation of trading of specified securities of listed entities.

The Exchange had also issued a guidance note regarding the provisions of the said SEBI circular which is disseminated on the Exchange website at the following link:

https://www.bseindia.com/downloads/1/Guidance_Note_for_SEBI_SOP_Circular.pdf

In this regard it is observed that the company is non-compliant/late compliant with the following Regulations for the period mentioned below:

Applicable Regulation of SEBI (LODR) Regulations, 2015	Fine prescribed (*)	Fines levied for	Fine payable by the company (Inclusive of GST @ 18 %) as on December 16, 2025			Compliance status	Discrepancy observed
			Basic Fine	GST @ 18 %	Total Fine payable		
Regulation 33 Non-submission of the financial results within the period prescribed under this regulation	Rs. 5,000/- per day till the date of compliance.	Sep-25	125000	22500	147500	Late submission	Financial Result late Submitted
Regulation 23 (9) Non-compliance with the requirement to disclose related party transactions in the format as specified and within the prescribed timeline.	Rs. 5,000/- per day till the date of compliance.	(for the half year ended September 2025)	0	0	0		
		Total SOP Fine	125000	22500	147500		

In case of non-submission/non-compliance, fine would be continued to be levied till the date of submission as per SEBI SOP Circular.

The Company is therefore advised to note that as per the provisions of this circular:

- The company is required to ensure compliance with above regulation and ensure to pay the aforesaid fines including GST within 15 days from the date of this letter/email, failing which Exchange shall, pursuant to the provisions of the aforesaid circular, initiate action related to freezing of the entire shareholding of the promoter in this entity as well as all other securities held in the demat account of the promoter. The company is advised to bring the provisions of this Circular to the notice of promoter of the company.

https://mail.hostinger.com/old/?_task=mail&_safe=0&_uid=24787&_mbox=INBOX&_action=print&_extwin=1

- Further in the event of this being the second consecutive year of non-compliance for the Regulation 33 would result in the company being transferred to Z group and liable for suspension of trading of its equity shares.
- The company is also advised to ensure that the subject matter of non-compliance which has been identified and indicated by the Exchange and any subsequent action taken by the Exchange in this regard shall be placed before the Board of Directors of the company in its next meeting. Comments made by the board shall be duly informed to the Exchange for dissemination.

Yours faithfully

Harshad Naik

Reena Raphel

Manager

Manager

Listing Compliance

Listing Compliance

In case of any further queries / clarifications please email the following ids:

Regulation	Officers name	Email Id	Contact Number
Reg.33/23(9)	Mr. Harshad Naik	Harshad.Naik@bseindia.com	022-22725650

Company is requested to remit the fine amount to the following designated **VIRTUAL BANK ACCOUNT** of the Exchange:

Company Name	Indrayani Biotech Ltd		
Account Name	Bank Name & Branch	Virtual Bank Account No.*	IFSC Code
BSE Limited	ICICI Bank Ltd.- CMS Branch	BSER04842	ICIC0000104

***Note: This bank account is specifically dedicated to SOP fine and Waiver fees only, Therefore, company is advised not to deposit/credit any amount payable other than SOP fines/penalties/waiver.**

The company is required to submit fine remittance details in the following format given at Annexure I to Email id: bse.soplodr@bseindia.com

Annexure-I (On letterhead of the company)

Sub: Details of Payment of fines for Non-Compliance with Regulations of SEBI (LODR) Regulations, 2015.

Remittance details:

Scrip Code	Regulation & Quarter	Bank UTR number	Date of Payment	Amount paid	TDS deducted, if any	Net Amount paid

Re: 526445-Reminder for freezing of promoter demat account (SEBI Master Circular No. SEBI/HO/CFD/PoD2/CIR/P/0155 dated November 11, 2024 (Chapter-VII(A)-Penal Actions for Non-Compliance).

From IBL COMPANY SECRETARY <cs@indrayani.com>
To bse.soplodr <bse.soplodr@bseindia.com>
Cc <info@indrayani.com>, <indrayanichennai@gmail.com>, RAMYA.MASH6@GMAIL.COM <RAMYA.MASH6@gmail.com>, JORAMESH@REDIFFMAIL.COM <JORAMESH@rediffmail.com>, <vedhaagathiyam@gmail.com>, <sidineshkumar@gmail.com>, <dkrulezstock@yahoo.com>, <ttsraja@gmail.com>, RAMESH@ADIETEXPRESS.CC <RAMESH@adietexpress.com>, <indirakumar@adietexpress.com>, [6 more...](#)
Date 02/01/2026 11:08 AM

Reg 33.pdf (~23 KB)

Dear Sir/Madam,

Company Name: Indrayani Biotech Limited**Scrip Code: 526445****Sub: Indrayani Biotech Limited - Remittance of fines**

Ref.: SOP-Review-dated- 15-12-2025

This is with regard to the fine levied by BSE for Non-submission of financial results for the quarter ended September '25, within the period prescribed under Regulation 33.

Subsequently, we have paid the above fine and the details are as below:

Scrip Code	Regulation & Quarter	Bank UTR number	Date of Payment	Amount paid (Rs.)	TDS deducted, if any	Net Amount paid (Rs.)
526445	Regulation 33 – September 2025	CMS5472050988	02/01/2026	147500	Nil	147500

We have also attached the screenshot of the payment for your reference. Kindly take the same on record.

Thanks & Regards,

Ramya Ravi

Company Secretary and Compliance Officer

526445-Fines as per SEBI Master Circular No. SEBI/HO/CFD/PoD2/CIR/P/0155 dated November 11, 2024 (Chapter-VII(A)-Penal Actions for Non-Compliance)

From bse.soplodr <bse.soplodr@bseindia.com>
To info@indrayani.com <info@indrayani.com>, indrayanichennai@gmail.com <indrayanichennai@gmail.com>, info@indrayani.com <info@indrayani.com>, CS@INDRAYANI.COM <CS@INDRAYANI.COM>
Cc bse.soplodr <bse.soplodr@bseindia.com>
Date 15/12/2025 05:03 PM

Ref.: SOP-CReview-dated- 15-12-2025

To

The Company Secretary/Compliance Officer

Company Name: Indrayani Biotech Ltd

Scrip Code: 526445

Dear Sir/Madam,

Sub: Fines as per SEBI Master Circular No. SEBI/HO/CFD/PoD2/CIR/P/0155 dated November 11, 2024 (Chapter-VII(A)-Penal Actions for Non-Compliance).

The company is advised to refer to the SEBI Master Circular No. SEBI/HO/CFD/PoD2/CIR/P/0155 dated November 11, 2024 issued by Securities and Exchange Board of India (SEBI) with respect to penal actions prescribed for non-compliance of certain provisions of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 and the Standard Operating Procedure for suspension and revocation of trading of specified securities of listed entities.

The Exchange had also issued a guidance note regarding the provisions of the said SEBI circular which is disseminated on the Exchange website at the following link:

https://www.bseindia.com/downloads1/Guidance_Note_for_SEBI_SOP_Circular.pdf

In this regard it is observed that the company is non-compliant/late compliant with the following Regulations for the period mentioned below:

Applicable Regulation of SEBI (LODR) Regulations, 2015	Basic Fine prescribed	Fines levied	Fine payable by the company (inclusive of GST @ 18 %)			Compliance status
			Basic Fine	GST @ 18 %	Total Fine payable	
Regulation 29(2)/29(3) Delay in furnishing prior intimation about the meeting of the board of directors	Rs. 10,000 per instance of non-compliance per item	For the month of November 2025	10000	1800	11800	-
Regulation 31A(3)(a) Non-compliance pertaining to delay in submission of reclassification application to stock exchanges	Rs. 5000 per day	For the month of November 2025	0	0	0	-
Regulation 44(3) Non-submission of the voting results within the period provided under this regulation	Rs. 10,000 per instance of non-compliance	For the month of November 2025	0	0	0	-
Regulation 42(2)/42(3)/42(4)/ 42(5) Delay in/ non-disclosure of record date/ dividend declaration or non-compliance with ensuring the specified time gap between two record dates/ book closure dates	Rs. 10,000 per instance of non-compliance	For the month of November 2025	0	0	0	-
		Total SOP Fine	10000	1800	11800	

The Company is therefore advised to note that as per the provisions of this circular:

- The company is required to ensure compliance with above regulation and ensure to pay the aforesaid fines including GST **within 15 days** from the date of this letter/email, **failing which Exchange shall, pursuant to the provisions of the aforesaid circular, initiate action related to freezing of the entire shareholding of the promoter in this entity as well as all other securities held in the demat account of the promoter.** The company is advised to bring the provisions of this Circular to the notice of promoter of the company.
- The company is also advised to ensure that the subject matter of non-compliance which has been identified and indicated by the Exchange and any subsequent action taken by the Exchange in this regard shall be placed before the Board of Directors of the company in its next meeting. Comments made by the board shall be duly informed to the Exchange for dissemination.

Yours faithfully,

Reena Raphel

Manager

Listing Compliance

Krishna Rathi

Deputy Manager

Listing Compliance

In case of any further queries / clarifications please email the following ids:

Regulation	Contact person	Email Id	Contact Number
Reg.29	Mr. Marian DSouza	listing.crd@bseindia.com ;	22728744
Reg.31A/44	Mr. Krishna Rathi	Krishna.Rathi@bseindia.com ;	22728747

Company is requested to remit the fine amount to the following designated **VIRTUAL BANK ACCOUNT** of the Exchange:

Company Name	Indrayani Biotech Ltd		
Account Name	Bank Name & Branch	Virtual Bank Account No.*	IFSC Code
BSE Limited	ICICI Bank Ltd.- CMS Branch	BSER04842	ICIC0000104

***Note: This bank account is specifically dedicated to SOP fine and Waiver fees only, Therefore, company is advised not to deposit/credit any amount payable other than SOP fines/penalties/waiver.**

The company is required to submit fine remittance details in the following format given at Annexure I to Email id: bse.soplodr@bseindia.com

Annexure-I (On letterhead of the company)

Sub: Details of Payment of fines for Non-Compliance with Regulations of SEBI (LODR) Regulations, 2015.

Remittance details:

Scrip Code	Regulation & Quarter	Bank UTR number	Date of Payment	Amount paid	TDS deducted, if any	Net Amount paid

--	--	--	--	--	--	--

This mail is classified as 'PUBLIC' by priya.gupta on December 15, 2025 at 17:03:26.

Re: 526445-Reminder for freezing of promoter demat account (SEBI Master Circular No. SEBI/HO/CFD/PoD2/CIR/P/0155 dated November 11, 2024 (Chapter-VII(A)-Penal Actions for Non-Compliance).

From IBL COMPANY SECRETARY <cs@indrayani.com>
To bse.soplodr <bse.soplodr@bseindia.com>
Cc <info@indrayani.com>, <indrayanichennai@gmail.com>, RAMYA.MASH6@GMAIL.COM <RAMYA.MASH6@gmail.com>, JORAMESH@REDIFFMAIL.COM <JORAMESH@rediffmail.com>, <vedhaagathyan@gmail.com>, <sidineshkumar@gmail.com>, <dkrulezstock@yahoo.com>, <ttsraja@gmail.com>, RAMESH@ADIETEXPRESS.CC <RAMESH@adietexpress.com>, INDIRAKUMARS.IK@GMAIL.COM <INDIRAKUMARS.IK@gmail.com>, [6 more...](#)
Date 02/01/2026 11:03 AM

Reg 29.pdf (~23 KB)

Dear Sir/Madam,

Company Name: Indrayani Biotech Limited**Scrip Code: 526445****Sub: Indrayani Biotech Limited - Remittance of fines**

Ref.: SOP-Review-dated- 15-12-2025

This is with regard to the fine levied by BSE with regard to delay in furnishing prior intimation about the meeting of the board of directors for the month of November'25 – Regulation 29(2)/29(3).

Subsequently, we have paid the above fine and the details are as below:

Scrip Code	Regulation & Quarter	Bank UTR number	Date of Payment	Amount paid (Rs.)	TDS deducted, if any	Net Amount paid (Rs.)
526445	Regulation 29(2)/29(3) – November 2025	CMS5472050988	02/01/2026	11800	Nil	11800

We have also attached the screenshot of the payment for your reference. Kindly take the same on record.

Thanks & Regards,

Ramya Ravi

Company Secretary and Compliance Officer